Loading...
•
Dec 30, 2023
Charles River Labs Q4 2023 Earnings Report
Charles River Labs' Q4 2023 results were announced, featuring a revenue decrease and earnings per share of $3.62.
Key Takeaways
Charles River Laboratories reported a Q4 2023 revenue of $1.01 billion, a 7.9% decrease compared to Q4 2022. GAAP earnings per share were $3.62, while non-GAAP earnings per share were $2.46. The company's performance reflected moderating demand trends in the life sciences sector.
Q4 revenue was $1.01 billion, a decrease of 7.9% year-over-year.
GAAP earnings per share were $3.62, a decrease of 0.8% year-over-year.
Non-GAAP earnings per share were $2.46, a decrease of 17.4% year-over-year.
GAAP operating margin decreased to 13.1% from 14.9% in the fourth quarter of 2022.
Revenue by Segment
Forward Guidance
The company is providing financial guidance for 2024. The 2024 revenue growth outlook reflects a continuation of the more cautious biopharmaceutical demand environment that the Company experienced throughout most of 2023.
Positive Outlook
- Revenue growth, reported 1.0% – 4.0%
- Impact of divestitures/(acquisitions), net ~(0.5)%
- (Favorable)/unfavorable impact of foreign exchange ~(0.5)%
- Revenue growth, organic (1) 0.0% – 3.0%
- Non-GAAP EPS estimate $10.90 – $11.40
Challenges Ahead
- Acquisition-related amortization (2) ~$2.40
- Acquisition and integration-related adjustments (3) ~$0.10
- Costs associated with restructuring actions (4) ~$0.25
- Other items (5) ~$0.25
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...